IMP3 and invasive carcinoma: Lu et al. [41] reported that IMP3 immunoreactivity is virtually absent in normal cervical epithelium and low-grade intraepithelial lesions but robust in high-grade cervical intraepithelial neoplasia and invasive carcinoma, where it predicts progression.